Clinical Trial Update: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing paclitaxel albumin-stabilized nanoparticles with or without AZD1775 in previously untreated metastatic or unresectable pancreatic canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer
• Unresectable Pancreatic Carcinoma

Drugs mentioned

• AZD1775 (Adavosertib)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation (paclitaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-04-25